Disease · MONDO_0005920
Comparisons in its trials27
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 27
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PA Group vs AL Group: deaths from any cause | 0 of 849 | 0 of 423 | 1,272 | NCT00422084 | Trial comparisons |
| PA Group vs AL Group: serious adverse events | 3 of 849 | 2 of 423 | 1,272 | NCT00422084 | Trial comparisons |
| Pyronaridine - Artesunate vs Mefloquine Plus Artesunate: deaths from any cause | 0 of 848 | 0 of 423 | 1,271 | NCT00403260 | Trial comparisons |
| Pyronaridine - Artesunate vs Mefloquine Plus Artesunate: serious adverse events | 6 of 848 | 3 of 423 | 1,271 | NCT00403260 | Trial comparisons |
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm | 146 of 154 | 151 of 156 | 310 | NCT03355664 | Trial comparisons |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Number of Severe Adverse Events by Study Arm | 2 of 154 | 5 of 156 | 310 | NCT03355664 | Trial comparisons |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: deaths from any cause | 0 of 154 | 0 of 156 | 310 | NCT03355664 | Trial comparisons |
| Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: serious adverse events | 2 of 154 | 5 of 156 | 310 | NCT03355664 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: deaths from any cause | 0 of 84 | 0 of 75 | 159 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: serious adverse events | 0 of 84 | 0 of 75 | 159 | NCT04222088 | Trial comparisons |
| ArTiMist vs Quinine: serious adverse events | 4 of 77 | 10 of 74 | 151 | NCT01258049 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Adequate Clinical and Parasitological Response (ACPR) | 74 of 75 | 72 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Early Treatment Failure (ETF) | 0 of 75 | 0 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Late Clinical Failure (LCF) | 1 of 75 | 0 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Late Parasitological Failure (LPF) | 0 of 75 | 2 of 74 | 149 | NCT04222088 | Trial comparisons |
| ArTiMist vs Quinine: Late Parasitological Failure | 12 of 70 | 14 of 71 | 141 | NCT01258049 | Trial comparisons |
| ArTiMist vs Quinine: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities | 5 of 70 | 6 of 71 | 141 | NCT01258049 | Trial comparisons |
| ArTiMist vs Quinine: Number of Deaths or Neurological Sequelae at Day 28 | 0 of 70 | 0 of 71 | 141 | NCT01258049 | Trial comparisons |
| ArTiMist vs Quinine: Late Clinical Failure | 3 of 70 | 1 of 71 | 141 | NCT01258049 | Trial comparisons |
| ArTiMist vs Quinine: Early Treatment Failure | 0 of 70 | 14 of 71 | 141 | NCT01258049 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005920/comparisons